XM n’offre pas ses services aux résidents des États-Unis d’Amérique.

Latest UK builder M&A may yet have completion date



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BREAKINGVIEWS-Latest UK builder M&A may yet have completion date</title></head><body>

The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Updates to add graphic.

By Yawen Chen

LONDON, June 14 (Reuters Breakingviews) -UK housebuilders’ consolidation trend is encountering some bumps in the road. While tougher times for the sector have seen the likes of Barratt Developments BDEV.L and Redrow RDW.L couple up, Crest Nicholson CRST.L on Friday said it had spurned a 650 million pound ($828 million) approach from 3 billion pound domestic rival Bellway BWY.L in May. That may not be the end of the story, though.

On the face of it, Crest has grounds to say no. Based off Bellway’s closing share price on Thursday, the all-share offer implies Crest is worth 253 pence a share – only a 19% premium to its own undisturbed level, whereas Barratt’s Redrow deal sported a 27% premium. Crest’s new chief executive poached from rival Persimmon PSN.L, Martyn Clark, has just started and may not want to sell out for less than the value of Crest’s net assets. And the company reckons that following a one-off 30 million pound charge related to poorly estimated development costs it is back on the straight and narrow.

Still, that charge was the fifth time in less than a year that Crest had unpleasantly surprised investors, and it has slashed its forecast adjusted pre-tax profit range. Even if antitrust authorities are probing Barratt’s Redrow deal, consolidation makes sense for Crest in particular and UK builders in general. Previously chunky returns on capital employed have slumped to single-digit levels, hampered by cost inflation and a housing market wrestling with higher interest rates that make it harder for buyers to take the plunge.

Bellway, whose own trading update last week was more upbeat, has scope to offer more. Recent sector deals have elicited synergies worth 3% to 4% of sales, Peel Hunt analysts reckon, which would amount to around 25 million pounds with a Crest deal. Taxed and capitalised, they could be worth around 190 million pounds in today’s money, more than the premium the suitor is offering.

The catch is that Crest’s latest profit warning implies Bellway should offer less, not more. Yet Crest shareholders may require only a nominal hike to play ball. And with a potential Labour government keen on cutting through UK planning constraints, Crest’s southeast England-focused operations may enjoy a revenue bump. If Bellway’s own investors agree, then a deal that looks stalled may yet happen.

Follow @ywchen1 on X


CONTEXT NEWS

British homebuilder Crest Nicholson said on June 14 rival Bellway’s revised and unsolicited 650 million pound ($828 million) all-share takeover offer “significantly undervalued” the group.

Bellway on June 13 made public a revised bid it had proposed on May 7, which valued Crest at 253 pence a share. The rejected proposal implied Crest Nicholson’s shareholders would own approximately 17.1% of the combined entity.

Earlier on June 13, Crest warned its annual adjusted pre-tax profit would drop by at least a third to be in the range of 22 million pounds to 29 million pounds, hurt by working through lower-margin sites and hit by a one-off cost.

An earlier offer was rejected in April, Crest said in a statement.

Martyn Clark takes over Crest as CEO from June 14.

As of 1121 GMT on June 14, Crest shares were trading at 2.36 pounds, up 10.4%. Bellway shares were trading at 25.96 pounds, down 4.5%.


Graphic: Crest Nicholson shares have lagged UK peers https://reut.rs/3yZ6V6O


Editing by George Hay and Oliver Taslic

</body></html>

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques